Modeling tumor development and metastasis using paired organoids derived from patients with colorectal cancer liver metastases

Tumor metastasis accounts for the majority of cancer-related deaths; it is therefore important to develop preclinical models that faithfully recapitulate disease progression. Here, we generated paired organoids derived from primary tumors and matched liver metastases in the same colorectal cancer (C...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of hematology and oncology 2020-09, Vol.13 (1), p.119-119, Article 119
Hauptverfasser: Li, He, Dai, Weixing, Xia, Xi, Wang, Renjie, Zhao, Jing, Han, Lingyu, Mo, Shaobo, Xiang, Wenqiang, Du, Lin, Zhu, Guangya, Xie, Jingjing, Yu, Jun, Liu, Nan, Huang, Mingzhu, Zhu, Jidong, Cai, Guoxiang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Tumor metastasis accounts for the majority of cancer-related deaths; it is therefore important to develop preclinical models that faithfully recapitulate disease progression. Here, we generated paired organoids derived from primary tumors and matched liver metastases in the same colorectal cancer (CRC) patients. Despite the fact that paired organoids exhibit comparable gene expression and cell morphology, organoids from metastatic lesions demonstrate more aggressive phenotypes, tumorigenesis, and metastatic capacity than those from primary lesions. Transcriptional analyses of the paired organoids reveal signature genes and pathways altered during the progression of CRC, including SOX2. Further study shows that inducible knockdown of SOX2 attenuated invasion, proliferation, and liver metastasis outgrowth. Taken together, we use patient-derived paired primary and metastatic cancer organoids to model CRC metastasis and illustrate that SOX2 is associated with CRC progression and may serve as a potential prognostic biomarker and therapeutic target of CRC.
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-020-00957-4